Just How Positive is Mizuho on Horizon Pharma (NASDAQ:HZNP) Following Their Upgrade?

January 13, 2018 - By Linda Rogers

  Just How Positive is Mizuho on Horizon Pharma (NASDAQ:HZNP) Following Their Upgrade?

Investors sentiment increased to 1 in 2017 Q3. Its up 0.08, from 0.92 in 2017Q2. It increased, as 33 investors sold Horizon Pharma Public Limited Company shares while 50 reduced holdings. 28 funds opened positions while 55 raised stakes. 132.29 million shares or 1.03% more from 130.94 million shares in 2017Q2 were reported.

Sg Americas Ltd Com owns 131,482 shares for 0.01% of their portfolio. Adams Diversified Equity Fund holds 47,800 shares. Drw Securities Ltd Liability Co accumulated 0.17% or 43,000 shares. Great Lakes Advsr Ltd holds 0.17% or 556,229 shares in its portfolio. Aqr Cap Mngmt Ltd owns 103,090 shares. Creative Planning holds 99,849 shares or 0.01% of its portfolio. The Luxembourg-based Artal Group has invested 0.11% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Citigroup reported 1.35M shares. State Common Retirement Fund accumulated 238,613 shares. Dimensional Fund Advsr Lp has 7.43M shares. Globeflex Cap Limited Partnership reported 62,393 shares or 0.23% of all its holdings. Moreover, D E Shaw has 0% invested in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Employees Retirement Association Of Colorado accumulated 28,442 shares. Connor Clark & Lunn Investment Management owns 194,105 shares. 270,775 were accumulated by Jw Asset Management Ltd.

Horizon Pharma (NASDAQ:HZNP) Stock Upgrade

Mizuho gave Horizon Pharma (NASDAQ:HZNP) shares a new Buy rating in an analyst note issued to investors and clients on Friday morning. The boost from the previous Neutral rating is certainly an interesting one.

Investors sentiment increased to 1 in 2017 Q3. Its up 0.08, from 0.92 in 2017Q2. It increased, as 33 investors sold Horizon Pharma Public Limited Company shares while 50 reduced holdings. 28 funds opened positions while 55 raised stakes. 132.29 million shares or 1.03% more from 130.94 million shares in 2017Q2 were reported.

Sg Americas Ltd Com owns 131,482 shares for 0.01% of their portfolio. Adams Diversified Equity Fund holds 47,800 shares. Drw Securities Ltd Liability Co accumulated 0.17% or 43,000 shares. Great Lakes Advsr Ltd holds 0.17% or 556,229 shares in its portfolio. Aqr Cap Mngmt Ltd owns 103,090 shares. Creative Planning holds 99,849 shares or 0.01% of its portfolio. The Luxembourg-based Artal Group has invested 0.11% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Citigroup reported 1.35M shares. State Common Retirement Fund accumulated 238,613 shares. Dimensional Fund Advsr Lp has 7.43M shares. Globeflex Cap Limited Partnership reported 62,393 shares or 0.23% of all its holdings. Moreover, D E Shaw has 0% invested in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Employees Retirement Association Of Colorado accumulated 28,442 shares. Connor Clark & Lunn Investment Management owns 194,105 shares. 270,775 were accumulated by Jw Asset Management Ltd.

Horizon Pharma Public Limited Company (NASDAQ:HZNP) Ratings Coverage

Among 13 analysts covering Horizon Pharma (NASDAQ:HZNP), 11 have Buy rating, 0 Sell and 2 Hold. Therefore 85% are positive. Horizon Pharma has $40 highest and $900 lowest target. $20.62’s average target is 35.84% above currents $15.18 stock price. Horizon Pharma had 54 analyst reports since September 9, 2015 according to SRatingsIntel. Morgan Stanley reinitiated Horizon Pharma Public Limited Company (NASDAQ:HZNP) rating on Thursday, December 3. Morgan Stanley has “Underweight” rating and $23.0 target. The firm earned “Buy” rating on Tuesday, November 8 by Mizuho. The rating was downgraded by Brean Capital to “Hold” on Tuesday, September 22. BMO Capital Markets maintained Horizon Pharma Public Limited Company (NASDAQ:HZNP) on Tuesday, September 26 with “Buy” rating. The firm has “Buy” rating by Stifel Nicolaus given on Friday, September 15. As per Tuesday, February 28, the company rating was maintained by Mizuho. The firm has “Buy” rating by UBS given on Thursday, November 30. Stifel Nicolaus maintained Horizon Pharma Public Limited Company (NASDAQ:HZNP) on Friday, October 20 with “Buy” rating. The stock of Horizon Pharma Public Limited Company (NASDAQ:HZNP) earned “Buy” rating by Mizuho on Monday, October 31. The stock has “Buy” rating by Jefferies on Monday, November 23.

The stock increased 0.60% or $0.09 during the last trading session, reaching $15.18. About 3.33M shares traded or 57.98% up from the average. Horizon Pharma Public Limited Company (NASDAQ:HZNP) has declined 28.13% since January 13, 2017 and is downtrending. It has underperformed by 44.83% the S&P500.

Analysts await Horizon Pharma Public Limited Company (NASDAQ:HZNP) to report earnings on February, 26. They expect $0.22 earnings per share, down 56.00 % or $0.28 from last year’s $0.5 per share. HZNP’s profit will be $36.06 million for 17.25 P/E if the $0.22 EPS becomes a reality. After $0.26 actual earnings per share reported by Horizon Pharma Public Limited Company for the previous quarter, Wall Street now forecasts -15.38 % negative EPS growth.

Horizon Pharma Public Limited Company, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally. The company has market cap of $2.49 billion. The companyÂ’s marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; PROCYSBI for the treatment of nephropathic cystinosis; QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients; and KRYSTEXXA to treat chronic refractory gout. It currently has negative earnings. The Company’s products also include RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and multiple other indications; DUEXIS to treat signs and symptoms of osteoarthritis and rheumatoid arthritis; MIGERGOT for the treatment of vascular headache; PENNSAID 2% to treat pain of osteoarthritis of the knees; and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

More notable recent Horizon Pharma Public Limited Company (NASDAQ:HZNP) news were published by: Seekingalpha.com which released: “Horizon Pharma Plc (HZNP) Q2 2017 Results – Earnings Call Transcript” on August 07, 2017, also Reuters.com with their article: “Horizon Pharma weighs sale of primary care unit -sources” published on September 15, 2017, Globenewswire.com published: “Horizon Pharma plc to Participate in BMO Prescriptions for Success Healthcare …” on November 30, 2017. More interesting news about Horizon Pharma Public Limited Company (NASDAQ:HZNP) were released by: Seekingalpha.com and their article: “Horizon Pharma Plc (HZNP) Q3 2017 Results – Earnings Call Transcript” published on November 06, 2017 as well as Seekingalpha.com‘s news article titled: “Horizon Pharma Plc (HZNP) Q1 2017 Results – Earnings Call Transcript” with publication date: May 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.